RIPK3 and central nervous system cancer: To validate these findings, we performed Western blot analyses across a clinical cohort of 81 glioma samples (16 grade II, 19 grade III, and 46 grade IV) (Fig. S2), which revealed significant upregulation of RIPK1 and MLKL and downregulation of RIPK3 in grade IV tumors relative to lower-grade gliomas (Fig. 1C).